OMAHA, Neb. (Oct. 17, 2014)—Promising research could lead to a significant and dramatic improvement in correctly diagnosing unstable coronary artery disease years, perhaps even decades, before traditional methods.
A scientific research journal, PLOS One, published in its September issue an article by a team of scientists at the University of Nebraska Medical Center who found a biomarker that could “allow for the assessment of a future cardiovascular event.”
The article—”Unique Antibody Responses to Malondialdehyde-Acetaldehyde (MAA)-Protein Adducts Predict Coronary Artery Disease“—significantly concludes that a biomarker could tell the difference between patients who harbor stable or unstable coronary artery disease. The difference between the two groups is the difference between living well into old age or suffering a sudden fatal heart attack at 40-years-old. Stable coronary artery disease is a manageable condition, but the unstable version is unpredictable and nearly impossible to diagnose.
Lead author and project collaborator, Dan Anderson, M.D., Ph.D., will discuss the research and its possible implications during UNMC Technology Demonstration Day on Oct. 21. Anderson, who is also a practicing cardiologist, will be among six others presenting some of the most recent and advanced innovations developed at UNMC and UNO laboratories.
Anderson and UNMC colleagues Geoffrey Thiele, Ph.D., and Michael Duryee are working on developing a simple blood test for the biomarker, which could give patients potentially years of advance warning if they carry the unstable version of the disease.
Such an early diagnosis could dramatically change how cardiologists treat patients, advancing cardiac care to an improved, more targeted and personalized approach.
Hosted by UNeMed, the technology transfer office at UNMC, Demo Day is a part of Innovation Week, a celebration of the research, discovery and innovation at UNMC. Demo Day is aimed at a general audience and is free and open for anyone to attend. Registrations are requested.